For millions of people with Alzheimer's, an experimental drug from Eli Lilly & Co. may be their last hope for treatment.

Pfizer and Johnson & Johnson pulled the plug Monday on their joint development of a similar therapy for Alzheimer's disease, after it failed to show any benefit in two late-stage studies. Lilly has said it will release its findings by the end of September.

The stakes are high, for the 5.4 million in the United States with Alzheimer's and for Lilly. No medicines on the market slow the progression of the disease, the most common form of dementia. If the Lilly drug succeeds, treatments could begin next year. Still, Lilly executives warn that a successful outcome for their solanezumab is a long shot.

With Pfizer and J&J having pulled out, investors give the Lilly drug a less than 20 percent chance of success. But treatments in development by other companies are still years away. -- Bloomberg News

Loading video…

PLUS: Working Moms: Making friends and Out East: Bedell Cellars Credit: Newsday

Updated now 2026 Holiday gift guide, Working Moms: Making friends and Out East: Bedell Cellars. Here's a look at some of the exclusive stories you may have missed this week on NewsdayTV.

Loading video…

PLUS: Working Moms: Making friends and Out East: Bedell Cellars Credit: Newsday

Updated now 2026 Holiday gift guide, Working Moms: Making friends and Out East: Bedell Cellars. Here's a look at some of the exclusive stories you may have missed this week on NewsdayTV.

Subscribe

Unlimited Digital AccessOnly 25¢for 6 months

SUBSCRIBESALE ENDS SOON | CANCEL ANYTIME